Peregrine Shares Gain on Bavituximab Phase IIb in NSCLC
Shares of Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) jumped more than 30 percent at Monday's opening bell before settling back to a 20.5 percent gain on positive top-line results from the company's randomized, double-blind, placebo-controlled Phase IIb study evaluating two dose levels of bavituximab plus docetaxel compared to docetaxel plus placebo in patients with second-line non-small-cell lung cancer (NSCLC).
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST